Journal
CLINICAL INFECTIOUS DISEASES
Volume 73, Issue 5, Pages 755-757Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab718
Keywords
Clostridioides difficile; guidelines; CDI
Categories
Funding
- Infectious Diseases Society of America
- Society for Healthcare Epidemiology of America
Ask authors/readers for more resources
This guideline offers focused updates on the management of Clostridioides difficile infection (CDI) in adults, specifically addressing the use of fidaxomicin and bezlotoxumab. Recommendations are based on evidence from systematic literature reviews and rated using the GRADE approach.
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA). This guideline is intended for use by healthcare professionals who care for adults with CDI, including specialists in infectious diseases, gastroenterologists, hospitalists, pharmacists, and any clinicians and healthcare providers caring for these patients. The panel's recommendations for the management CDI are based upon evidence derived from topic-specific systematic literature reviews. Summarized below are the recommendations for the management of CDI in adults. The panel followed a systematic process which included a standardized methodology for rating the certainty of the evidence and strength of recommendation using the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). A detailed description of background, methods, evidence summary and rationale that support each recommendation, and knowledge gaps can be found online in the full text.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available